



PATENT  
ATTORNEY DOCKET NO. CIT1510-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory Cope, et al.  
Serial No.: 10/047,253  
Filed: January 14, 2002  
Title: REGULATION OF TARGET PROTEIN ACTIVITY THROUGH MODIFIER PROTEINS

Art Unit: 1652  
Examiner: Y. D. Pak

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

10/21/2004 KBETEMA1 00000003 10047253

01 FC:1806

180.00 DP

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on October 18, 2004, in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Stephanie Sharrett*  
Stephanie Sharrett


Gray Cary\GT6418255.1  
104659-184  
GT\6418936.1  
104662-94

In re Application of:  
Gregory Cope, et al.  
Application No.: 10/047,253  
Filed: January 14, 2002  
Page 2

PATENT  
Attorney Docket No.: CIT1510-4

Check No. 564168 in the amount of \$180.00 is enclosed for the requisite fee and Applicants do not believe any other fees are due in connection with this Supplemental Information Disclosure Statement. However, if any fees are required, authorization is hereby given to charge Deposit Account No. 50-1355. A duplicate copy of this Transmittal sheet is enclosed.

Respectfully submitted,



Lisa A. Haile  
Lisa A. Haile, Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

**USPTO CUSTOMER NUMBER 28213**  
GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, CA 92121-2133

In Re Application of:

Gregory Cope, et al.

Application Serial No.: 10/047,253

Filed: January 14, 2002

Page 2



PATENT

Attorney Docket No.: CIT1510-4

This Supplemental Information Disclosure Statement is being filed before the mailing date of a final office or the notice of allowance. Each item contained herewith was cited in a communication from a foreign patent office in a counterpart foreign application more than three months prior to the filing of this information disclosure statement. Therefore, the requisite fee of \$180.00 is enclosed, and Applicants do not believe any other fees are due in connection with this submission. However, the Commissioner is hereby authorized to charge any amounts required by this filing, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: October 18, 2004

Lisa A. Haile, Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
**USPTO Customer No. 28213**



1652

PATENT  
Attorney Docket No.: CIT1510-4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory Cope, et al. Art Unit: 1652  
Application No.: 10/047,253 Examiner: Y. D. Pak  
Filed: January 14, 2002  
Title: REGULATION OF TARGET PROTEIN ACTIVITY THROUGH  
MODIFIER PROTEINS


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL SHEET**


Sir:

Transmitted herewith for the above-identified application, please find:

- (1) A Supplemental Information Disclosure Statement (2 pages);
- (2) A Form PTO-1449 (1 page);
- (3) International Search Report (6 pages);
- (4) Nine (9) References;
- (5) Check No. 564168 in the amount of \$180.00; and
- (6) Return postcard;

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, October 18, 2004, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
 _____ Stephanie Sharrett <small>(Name of Person Mailing Paper)</small>	
October 18, 2004	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. CIT1510-4	Serial No.: 10/047,253
	Applicant(s): Gregory Cope, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: January 14, 2002	Group Art Unit: 1645



### U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
A	WO00/79267	12/28/00	PCT			
B	EP1 130 029	9/5/01	EPO			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

C	Bech-Otschir, et al., "COP9 Signalsome-specific Phosphorylation Target p53 to Degradation by the Ubiquitin System", <i>The EMBO J.</i> 20(7):1630-1639, (2001).
D	Ciechanover, et al., "Ubiquitin-mediated Proteolysis: Biological Regulation Via Destruction", <i>BioEssays</i> 22:442-451, (2000).
E	Eytan, et al., "Ubiquitin C-terminal Hydrolase Activity Associated with the 26 S Protease Complex", <i>J. of Bio. Chem.</i> 268(7):4668-4674, (March 1993).
F	Löwe, et al., "Crystal Structure of the 20S Proteasome from the Archaeon <i>T. acidophilum</i> at 3.4 Å Resolution", <i>Sci.</i> , 268:533-539, (April 1995).
G	Lyapina, et al., "Promotion of NEDD8-CUL1 Conjugate Cleavage by COP9 Signalsome", <i>Sci.</i> 292:1382-1385, (May 2001).
H	Tomoda, et al., "Degradation of the Cyclin-dependent-kinase Inhibitor p27 <sup>kip1</sup> is instigated by Jab1", <i>Nat.</i> 398:160-165, (March 1999).
I	Wei, et al., "The COP9 Complex is Conserved Between Plants and Mammals and is Related to the 26S Proteasome Regulatory Complex", <i>Cur. Bio.</i> 8(16):919-922, (1998).

EXAMINER  GT6418900.1 104662-94	DATE CONSIDERED
--	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.